Speaker(s): 

Lindsey Burton, MD, Resident Physician, Geisinger - has nothing to disclose.

Sara Waqar, MD, Resident Physician, Geisinger - has nothing to disclose.

Moderator(s): 

Zachary Hoffer, MD, Pathology Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Evaluate the role of ROSE in trial-associated FNA procedures
• Describe the best predictors of adequacy and mortality in FNA procedures
• Evaluate myeloid neoplasm classifications, explaining the two major types of classification systems
• Describe the Real-world impact the two types of myeloid neoplasm classification systems on patient diagnoses

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Zachary S. Hoffer, MD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commerical Support for this Session: 

None.